New GLP-1 drugs coming: the 2026–2027 pipeline
CagriSema, retatrutide and other upcoming obesity and diabetes drugs: status, results and expected decisions.
Key point
None of the investigational products is legally sold. Anything marketed as one online is unapproved.
- CagriSema (Novo Nordisk): filed with the FDA December 2025; decision expected Q4 2026.
- Retatrutide (Lilly): triple agonist; FDA submission planned for Q1 2027 after positive phase 3 results.
- Ozempic tablets 25 mg: under FDA review, decision expected by end of 2026.
- Survodutide (Boehringer Ingelheim / Zealand Pharma) and other agents remain in development.
Sources
Checked against these primary sources on .